{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T22:24:43Z","timestamp":1743978283004,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir Vet J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic hypertension affects the heart, and to the best of our knowledge, no study has investigated the effects of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in dogs with myxomatous mitral valve disease (MMVD) stage B and systemic hypertension. This study aimed to investigate the blood level of NT-proBNP and assess the selected echocardiographic variables in dogs with MMVD stage B according to the presence of systemic hypertension or normal blood pressure and in dogs without MMVD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study group comprised 37 dogs with stage B MMVD (normotensive group, <jats:italic>n<\/jats:italic>\u2009=\u200930; systemic hypertension group, <jats:italic>n<\/jats:italic>\u2009=\u20097) and 13 dogs without MMVD. We evaluated NT-proBNP, blood pressure, complete blood count (CBC), and serum chemistry in all 50 dogs. We performed electrocardiography, radiography, and echocardiography on 44 dogs (37 dogs with MMVD and 7 dogs without MMVD). The NT-proBNP concentrations showed significant intergroup differences (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Normotensive dogs with MMVD stage B (median [interquartile range]: 1083.5 [574.8\u20131912.8] pmol\/L) and hypertensive dogs with MMVD stage B (2345.0 [1812.5\u20132533.0] pmol\/L) showed significantly higher NT-proBNP concentrations than dogs without MMVD (504 [430\u2013774] pmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.009 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively), and dogs in the systemic hypertension group showed significantly higher NT-proBNP concentrations than those in the normotensive group (<jats:italic>p<\/jats:italic>\u2009=\u20090.046). Mitral valve regurgitation velocity was significantly higher in dogs in the systemic hypertension group (6.11 [6.07\u20136.24] m\/s) than in those in the normotensive group (5.53 [5.17\u20135.95] m\/s, <jats:italic>p<\/jats:italic>\u2009=\u20090.006). The left atrial to aortic root ratio (LA\/Ao), E-peak velocity, and left ventricular end\u2010diastolic internal diameter corrected for body weight (LVIDDN) were significantly lower in dogs without MMVD than in dogs with MMVD stage B.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings suggest that NT-proBNP concentrations are higher in dogs with MMVD stage B with systemic hypertension than in normotensive dogs with MMVD stage B. Therefore, clinicians should be aware that NT-proBNP could be elevated in the presence of systemic hypertension.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13620-023-00233-0","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T10:06:49Z","timestamp":1675850809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["N-terminal pro\u2013B-type natriuretic peptide\u00a0levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B"],"prefix":"10.1186","volume":"76","author":[{"given":"In Sung","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Kyoung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-695X","authenticated-orcid":false,"given":"Eun Wha","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"issue":"1","key":"233_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1749-6632.1965.tb49421.x","volume":"127","author":"DK Detweiler","year":"2006","unstructured":"Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs*. Ann N Y Acad Sci. 2006;127(1):481\u2013516.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"233_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1740-8261.2009.01559.x","volume":"50","author":"E Terzo","year":"2009","unstructured":"Terzo E, Di Marcello M, McALLISTER H, Glazier B, Lo Coco D, Locatelli C, et al. Echocardiographic assessment of 537 dogs with mitral valve prolapse and leaflet involvement. Vet Radiol Ultrasound. 2009;50(4):416\u201322.","journal-title":"Vet Radiol Ultrasound"},{"issue":"4","key":"233_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cvsm.2010.03.008","volume":"40","author":"M Borgarelli","year":"2010","unstructured":"Borgarelli M, Haggstrom J. Canine Degenerative Myxomatous Mitral Valve Disease: Natural History, Clinical Presentation and Therapy. Vet Clin North Am Small Anim Pract. 2010;40(4):651\u201363.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"3","key":"233_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","volume":"33","author":"BW Keene","year":"2019","unstructured":"Keene BW, Atkins CE, Bonagura JD, Fox PR, H\u00e4ggstr\u00f6m J, Fuentes VL, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33(3):1127\u201340.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"233_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/jvim.15331","volume":"32","author":"MJ Acierno","year":"2018","unstructured":"Acierno MJ, Brown S, Coleman AE, Jepson RE, Papich M, Stepien RL, et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018;32(6):1803\u201322.","journal-title":"J Vet Intern Med"},{"key":"233_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1748-5827.2009.00800.x","volume":"50","author":"J H\u00e4ggstr\u00f6m","year":"2009","unstructured":"H\u00e4ggstr\u00f6m J, H\u00f6glund K, Borgarelli M. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease. J Small Anim Pract. 2009;50:25\u201333.","journal-title":"J Small Anim Pract"},{"issue":"4","key":"233_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cvsm.2010.03.004","volume":"40","author":"MA Oyama","year":"2010","unstructured":"Oyama MA, Singletary GE. The Use of NT-proBNP Assay in the Management of Canine Patients with Heart Disease. Vet Clin North Am Small Anim Pract. 2010;40(4):545\u201358.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"8","key":"233_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.amjcard.2004.12.032","volume":"95","author":"JL Januzzi","year":"2005","unstructured":"Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948\u201354.","journal-title":"Am J Cardiol"},{"issue":"3","key":"233_CR9","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.amjcard.2007.11.017","volume":"101","author":"JL Januzzi","year":"2008","unstructured":"Januzzi JL, Chen-Tournoux AA, Moe G. Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms. Am J Cardiol. 2008;101(3):S29-38.","journal-title":"Am J Cardiol"},{"issue":"6","key":"233_CR10","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jacc.2004.06.015","volume":"44","author":"A Maisel","year":"2004","unstructured":"Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). J Am Coll Cardiol. 2004;44(6):1328\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"233_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0300-8932(04)77124-9","volume":"57","author":"M Rivera","year":"2004","unstructured":"Rivera M, Tal\u00e9ns-Visconti R, Salvador A, Bertomeu V, Mir\u00f3 V, Garc\u00eda de Burgos F, et al. NT-proBNP Levels and Hypertension Their Importance in the Diagnosis of Heart Failure. Rev Esp Cardiol Engl Ed. 2004;57(5):396\u2013402.","journal-title":"Rev Esp Cardiol Engl Ed."},{"issue":"2","key":"233_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jvc.2016.11.001","volume":"19","author":"RL Winter","year":"2017","unstructured":"Winter RL, Saunders AB, Gordon SG, Buch JS, Miller MW. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Cardiol. 2017;19(2):124\u201331.","journal-title":"J Vet Cardiol"},{"issue":"3","key":"233_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jvim.14655","volume":"31","author":"ES Bijsmans","year":"2017","unstructured":"Bijsmans ES, Jepson RE, Wheeler C, Syme HM, Elliott J. Plasma N-Terminal Probrain Natriuretic Peptide, Vascular Endothelial Growth Factor, and Cardiac Troponin I as Novel Biomarkers of Hypertensive Disease and Target Organ Damage in Cats. J Vet Intern Med. 2017;31(3):650\u201360.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"233_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1740-8261.2012.01976.x","volume":"54","author":"K Jepsen-Grant","year":"2013","unstructured":"Jepsen-Grant K, Pollard RE, Johnson LR. Vertebral Heart Scores In Eight Dog Breeds. Vet Radiol Ultrasound. 2013;54(1):3\u20138.","journal-title":"Vet Radiol Ultrasound"},{"issue":"2","key":"233_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0008-6363(00)00113-9","volume":"47","author":"H Pedersen","year":"2000","unstructured":"Pedersen H. Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. Cardiovasc Res. 2000;47(2):234\u201343.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"233_CR16","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/jvim.14586","volume":"30","author":"A Boswood","year":"2016","unstructured":"Boswood A, H\u00e4ggstr\u00f6m J, Gordon SG, Wess G, Stepien RL, Oyama MA, et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. J Vet Intern Med. 2016;30(6):1765\u201379.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"233_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jvc.2012.01.006","volume":"14","author":"HG Parker","year":"2012","unstructured":"Parker HG, Kilroy-Glynn P. Myxomatous mitral valve disease in dogs: Does size matter? J Vet Cardiol. 2012;14(1):19\u201329.","journal-title":"J Vet Cardiol"},{"issue":"3","key":"233_CR18","first-page":"211","volume":"70","author":"CE Haberman","year":"2006","unstructured":"Haberman CE, Kang CW, Morgan JD, Brown SA. Evaluation of oscillometric and Doppler ultrasonic methods of indirect blood pressure estimation in conscious dogs. Can J Vet Res. 2006;70(3):211\u20137.","journal-title":"Can J Vet Res"},{"issue":"5\u20136","key":"233_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1440-1681.2003.03841.x","volume":"30","author":"CJ Thomas","year":"2003","unstructured":"Thomas CJ, Woods RL. Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. Clin Exp Pharmacol Physiol. 2003;30(5\u20136):369\u201375.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"233_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejheart.2004.01.001","volume":"6","author":"P Hildebrandt","year":"2004","unstructured":"Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis. Eur J Heart Fail. 2004;6(3):313\u20137.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"233_CR21","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2460\/javma.232.10.1496","volume":"232","author":"MA Oyama","year":"2008","unstructured":"Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc. 2008;232(10):1496\u2013503.","journal-title":"J Am Vet Med Assoc"},{"issue":"3","key":"233_CR22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1939-1676.2012.00916.x","volume":"26","author":"GE Singletary","year":"2012","unstructured":"Singletary GE, Rush JE, Fox PR, Stepien RL, Oyama MA. Effect of NT-pro-BNP Assay on Accuracy and Confidence of General Practitioners in Diagnosing Heart Failure or Respiratory Disease in Cats with Respiratory Signs. J Vet Intern Med. 2012;26(3):542\u20136.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"233_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1939-165X.2011.00305.x","volume":"40","author":"G Wess","year":"2011","unstructured":"Wess G, Daisenberger P, Mahling M, Hirschberger J, Hartmann K. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats: NT-proBNP and hypertrophic cardiomyopathy in cats. Vet Clin Pathol. 2011;40(2):237\u201344.","journal-title":"Vet Clin Pathol"},{"issue":"1","key":"233_CR24","first-page":"9","volume":"8","author":"RA Baisan","year":"2016","unstructured":"Baisan RA, Rosa AD, Loria AD, Vulpe V, Piantedosi D. Cardiac biomarkers in clinical practice of dog and cat \u2013 a review. Human and Veterinary Medicine. 2016;8(1):9.","journal-title":"Human and Veterinary Medicine"},{"issue":"2","key":"233_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tvjl.2007.12.026","volume":"180","author":"I Tarnow","year":"2009","unstructured":"Tarnow I, Olsen LH, Kvart C, Hoglund K, Moesgaard SG, Kamstrup TS, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J. 2009;180(2):195\u2013201.","journal-title":"Vet J"}],"container-title":["Irish Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13620-023-00233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13620-023-00233-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13620-023-00233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T10:11:07Z","timestamp":1675851067000},"score":1,"resource":{"primary":{"URL":"https:\/\/irishvetjournal.biomedcentral.com\/articles\/10.1186\/s13620-023-00233-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1186\/s13620-023-00233-0","relation":{},"ISSN":["2046-0481"],"issn-type":[{"type":"electronic","value":"2046-0481"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was reviewed and approved by the Institutional Animal Care and Use Committee. (Approval number KW-181210\u20131), South Korea. Informed consent was obtained from each dog owner.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}